

101 791 278

Cofc

ARNOLD & PORTER LLP

Suet M. Chong
Suet.Chong@aporter.com

EJ

202.942.5849
202.942.5999 Fax

555 Twelfth Street, NW
Washington, DC 20004-1206

August 1, 2007



Attn: Certificate of Correction
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate
AUG 03 2007
of Correction

Re: U.S. Patent No. 7,125,907 B2
Issued: October 24, 2006
Title: Thiolactones
Patentees: Barbara S. SLUSHER *et al.*
Atty. Docket No.: P30691US01/20595.171

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office, Certificate of Corrections Branch:

1. a letter;
2. an original Certificate of Correction with corrections indicated in red ink; and
3. a return postcard.

Please stamp the attached postcard with the filing date of these documents and return it to our courier.

Patentees do not believe any fees are due in conjunction with this filing. However, if any fees are required in the present application, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter LLP Deposit Account No. 50-2387, referencing matter number P30691US01/20595.171.

Respectfully submitted,

Suet M. Chong (Reg. No. 38,104)

Attachments



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent of:

Confirmation No.: 8933

Barbara S. SLUSHER *et al.*

Group Art Unit: 1626

Patent No.: 7,125,907

Examiner: Susannah L. CHUNG

Issued: October 24, 2006

Atty. Docket: P30691US01/20595.171

Title: Thiolactones

LETTER

Attn: Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to a telephone conference with Ms. Omega Lewis of the Certificate of Corrections Branch at the U.S. Patent and Trademark Office (USPTO), Patentees hereby request that a new Certificate of Correction be issued to reflect the following corrections:

claim 5, second line, please insert "I" after the word "formula";


claim 6, please insert a comma before the word "wherein"; and

claim 6, please replace the word "substiutted" with "substituted".

At Ms. Lewis' request, the above-identified corrections are marked on the attached original Certificate of Correction in red ink. Support for these corrections may be found in the USPTO records, including Patentees' Request for Certificate of Correction Under 37 C.F.R. §§ 1.322 and 1.323 filed on March 23, 2007.

Patentees believe that because the corrections are necessitated as a result of Patent Office errors, no fees are due in conjunction with this filing. However, if any fees are required, Patentees hereby authorize the Commissioner to charge such fees to Arnold & Porter LLP Deposit Account No. 50-2387, referencing docket number P30691US01/20595.171.

Respectfully submitted,



Suet M. Chong (Reg. Atty. No. 38,104)

Date: August 1, 2007

ARNOLD & PORTER LLP
Attn: IP Docketing
555 Twelfth Street, N.W.
Washington, D.C. 20004-1206
(202) 942-5000 telephone
(202) 942-5999 facsimile

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 7,125,907 B2
APPLICATION NO. : 10/791278
DATED : October 24, 2006
INVENTOR(S) : Barbara S. Slusher et al.

Page 1 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At Column 32, lines 20-58, please replace claim 1 with claim 1 as follows:

1. A compound of formula I



or a pharmaceutically acceptable equivalent, an optical isomer or a mixture of isomers of the compound, wherein:

X is C₁-C₄ alkylene, C₂-C₄ alkenylene, C₂-C₄ alkynylene, C₃-C₈ cycloalkylene, C₅-C₇ cycloalkenylene or Ar, wherein the alkylene, alkenylene, alkynylene, cycloalkylene or cycloalkenylene is unsubstituted or substituted with one or more substituent(s);

L is a bond, -CR¹R²-, -O-, -S-, -SO₂- or -NR¹-;

Y is -CR³R⁴-;

Z is -(CR⁵R⁶)_n-;

n is 2;

Ar is a bivalent aryl or heteroaryl radical that is unsubstituted or substituted with one or more substituent(s); and

R¹, R², R³, R⁴, R⁵ and R⁶ are independently hydrogen, C₁-C₄ alkyl or C₂-C₄ alkenyl, wherein the alkyl or alkenyl is unsubstituted or substituted with one or more substituent(s).

At Column 33, lines 8-10, please replace claim 5 with claim 5 as follows:

5. A method of treating peripheral neuropathy, comprising administering to a mammal in need of such treatment, an effective amount of a compound of formula of claim 1.

↑
I

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 7,125,907 B2
APPLICATION NO. : 10/791278
DATED : October 24, 2006
INVENTOR(S) : Barbara S. Slusher et al.

Page 2 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At Column 33, line 12, through Column 34, line 21, please replace claim 6 with claim 6 as follows:

6. A pharmaceutical composition comprising:
(i) an effective amount of a compound of formula I



or a pharmaceutically acceptable equivalent, an optical isomer or a mixture of isomers of the compound, wherein:

X is C₁-C₄ alkylene, C₂-C₄ alkenylene, C₂-C₄ alkynylene, C₃-C₈ cycloalkylene, C₅-C₇ cycloalkenylene or Ar, wherein the alkylene, alkenylene, alkynylene, cycloalkylene or cycloalkenylene is unsubstituted or substituted with one or more substituent(s);

L is a bond, -CR¹R²-, -O-, -S-, -SO₂- or -NR¹-;

Y is -CR³R⁴-;

Z is -(CR⁵R⁶)_n-;

n is 2;

Ar is a bivalent aryl or heteroaryl radical that is unsubstituted or substituted with one or more substituent(s);

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,125,907 B2
APPLICATION NO. : 10/791278
DATED : October 24, 2006
INVENTOR(S) : Barbara S. Slusher et al.

Page 3 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At Column 33, line 12, through Column 34, line 21, please replace claim 6 with claim 6 as follows (cont'd):

R¹, R², R³, R⁴, R⁵ and R⁶ are independently hydrogen, C₁-C₄ alkyl or C₂-C₄ alkenyl, wherein the alkyl or alkenyl is unsubstituted or ~~substituted~~ **SUBSTITUTED** with one or more substituent(s); and
(ii) a pharmaceutically acceptable carrier.



Signed and Sealed this

Eighth Day of May, 2007

JON W. DUDAS
Director of the United States Patent and Trademark Office